Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma

被引:83
|
作者
Chua, Daniel T. T. [1 ]
Wei, William I. [2 ]
Wong, Maria P. [3 ]
Sham, Jonathan S. T. [1 ]
Nicholls, John [3 ]
Au, Gordon K. H. [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China
[2] Univ Hong Kong, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[3] Univ Hong Kong, Queen Mary Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China
关键词
nasopharyngeal carcinoma; gefitinib; epidermal growth factor receptor; recurrence; distant metastases;
D O I
10.1002/hed.20792
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. This single-center, phase II study assessed the safety/tolerability and initial efficacy of gefitinib in patients with nasopharyngeal carcinoma (NPC) pretreated with platinum-based chemotherapy. Methods. Patients with recurrent and metastatic NPC who had treatment failure with at least 2 lines of chemotherapy including platinum were given gefitinib at a fixed dose of 250 mg daily. Treatment was continued until the patient experienced unacceptable side effects or disease progression. Results, Nineteen patients were enrolled, having had treatment failure with a median of 2 chemotherapy regimens. Treatment was well tolerated, and only grades 1 to 2 adverse events were observed. None of the patients achieved partial or complete response, Median time-to-progression was 4 months, and median overall survival was 16 months. Conclusion. Gefitinib was well tolerated, but the response rate was poor in this heavily pretreated study population, and its use in NPC is not recommended outside the context of clinical trial. (c) 2008 Wiley Periodicals, Inc.
引用
收藏
页码:863 / 867
页数:5
相关论文
共 50 条
  • [1] A phase II trial of gefitinib in recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy
    Chua, D. T.
    Sham, J.
    Au, G.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Anlotinib for patients with recurrent or metastatic nasopharyngeal carcinoma: A phase II study.
    Cai, Qingqing
    Su, Ning
    Fang, Yu
    Zou, Qihua
    Xia, Yi
    Ma, Shuyun
    Cai, Jun
    Liu, PanPan
    Wang, Jinni
    Zhang, Yuchen
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18020 - E18020
  • [3] A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
    Lim, Wan-Teck
    Ng, Quan-Sing
    Ivy, Percy
    Leong, Swan-Swan
    Singh, Onkar
    Chowbay, Balram
    Gao, Fei
    Thng, Choon Hua
    Goh, Boon-Cher
    Tan, Daniel Shao-Weng
    Koh, Tong San
    Toh, Chee-Keong
    Tan, Eng-Huat
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5481 - 5489
  • [4] A phase II study of axitinib in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).
    Hui, Edwin Pun
    Ma, Brigette
    Mo, Frankie
    Kam, Michael K. M.
    Chan, Stephen Lam
    Loong, Herbert H. F.
    Ho, Rosalie
    Leung, Sing Fai
    King, Ann Dorothy
    Wang, Ki
    Ahuja, Anil Tejbhan
    Chan, Charles
    Hui, Connie W. C.
    Wong, Chi Hang
    Chan, Anthony T. C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
    Mo, Yunyan
    Pan, Yufei
    Zhang, Bin
    Zhang, Jian
    Su, Yixin
    Liu, Zhengchun
    Luo, Meiqing
    Qin, Guanjie
    Kong, Xiangyun
    Zhang, Rongjun
    Pan, Yu
    Liang, Yi
    Wang, Defeng
    Wei, Yuejia
    Chen, Hengwei
    Jiang, Wei
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [6] Phase II study of gefitinib in patients with metastatic/recurrent squamous cell carcinoma of the skin.
    Glisson, B. S.
    Kim, E. S.
    Kies, M. S.
    Francisco, M.
    Blumenschein, G. R.
    Tsao, A. S.
    Clayman, G. L.
    Duvic, M.
    Weber, R. S.
    Lippman, S. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 287S - 287S
  • [7] A phase II study of sorafenib in combination with cisplatin and 5-fluorouracil in the treatment of recurrent or metastatic nasopharyngeal carcinoma
    Xue, Cong
    Yu, Qitao
    Pan, Jian-ji
    Sun, Yuanlu
    Zhang, Li
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study
    Ngan, RKC
    Yiu, HHY
    Lau, WH
    Yau, S
    Cheung, FY
    Chan, TM
    Kwok, CH
    Chiu, CY
    Au, SK
    Foo, W
    Law, CK
    Tse, KC
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (08) : 1252 - 1258
  • [9] Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
    Chan, ATC
    Hsu, MM
    Goh, BC
    Hui, EP
    Liu, TW
    Millward, MJ
    Hong, RL
    Whang-Peng, J
    Ma, BBY
    To, KF
    Mueser, M
    Amellal, N
    Lin, X
    Chang, AY
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) : 3568 - 3576
  • [10] A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
    McCarthy, JS
    Tannock, IF
    Degendorfer, P
    Panzarella, T
    Furlan, M
    Siu, LL
    [J]. ORAL ONCOLOGY, 2002, 38 (07) : 686 - 690